ABSTRACT
We report the results of whole-genome and transcriptome sequencing of tumor and adjacent normal tissue samples from 17 patients with non-small cell lung carcinoma (NSCLC). We identified 3,726 point mutations and more than 90 indels in the coding sequence, with an average mutation frequency more than 10-fold higher in smokers than in never-smokers. Novel alterations in genes involved in chromatin modification and DNA repair pathways were identified, along with DACH1, CFTR, RELN, ABCB5, and HGF. Deep digital sequencing revealed diverse clonality patterns in both never-smokers and smokers. All validated EFGR and KRAS mutations were present in the founder clones, suggesting possible roles in cancer initiation. Analysis revealed 14 fusions, including ROS1 and ALK, as well as novel metabolic enzymes. Cell-cycle and JAK-STAT pathways are significantly altered in lung cancer, along with perturbations in 54 genes that are potentially targetable with currently available drugs.
Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Smoking/genetics , Smoking/pathology , Carcinoma, Non-Small-Cell Lung/therapy , Chromosome Aberrations , Female , Gene Expression Profiling , Genome-Wide Association Study , High-Throughput Nucleotide Sequencing , Humans , INDEL Mutation , Lung Neoplasms/therapy , Male , Molecular Targeted Therapy , Point Mutation , Reelin ProteinABSTRACT
In this work, we present the Genome Modeling System (GMS), an analysis information management system capable of executing automated genome analysis pipelines at a massive scale. The GMS framework provides detailed tracking of samples and data coupled with reliable and repeatable analysis pipelines. The GMS also serves as a platform for bioinformatics development, allowing a large team to collaborate on data analysis, or an individual researcher to leverage the work of others effectively within its data management system. Rather than separating ad-hoc analysis from rigorous, reproducible pipelines, the GMS promotes systematic integration between the two. As a demonstration of the GMS, we performed an integrated analysis of whole genome, exome and transcriptome sequencing data from a breast cancer cell line (HCC1395) and matched lymphoblastoid line (HCC1395BL). These data are available for users to test the software, complete tutorials and develop novel GMS pipeline configurations. The GMS is available at https://github.com/genome/gms.
Subject(s)
Chromosome Mapping/methods , Genome, Human/genetics , Knowledge Bases , Models, Genetic , Sequence Analysis, DNA/methods , User-Computer Interface , Algorithms , Computer Simulation , Database Management Systems , Databases, Genetic , Humans , Sequence Alignment/methodsABSTRACT
Massively parallel DNA sequencing technologies provide an unprecedented ability to screen entire genomes for genetic changes associated with tumour progression. Here we describe the genomic analyses of four DNA samples from an African-American patient with basal-like breast cancer: peripheral blood, the primary tumour, a brain metastasis and a xenograft derived from the primary tumour. The metastasis contained two de novo mutations and a large deletion not present in the primary tumour, and was significantly enriched for 20 shared mutations. The xenograft retained all primary tumour mutations and displayed a mutation enrichment pattern that resembled the metastasis. Two overlapping large deletions, encompassing CTNNA1, were present in all three tumour samples. The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour.
Subject(s)
Brain Neoplasms/genetics , Brain Neoplasms/secondary , Breast Neoplasms/genetics , Genome, Human/genetics , Mutation/genetics , Neoplasm Transplantation , Adult , Breast Neoplasms/pathology , DNA Copy Number Variations/genetics , DNA Mutational Analysis , Disease Progression , Female , Gene Frequency/genetics , Genomics , Humans , Translocation, Genetic/genetics , Transplantation, Heterologous , alpha Catenin/geneticsABSTRACT
Massively parallel sequencing technology and the associated rapidly decreasing sequencing costs have enabled systemic analyses of somatic mutations in large cohorts of cancer cases. Here we introduce a comprehensive mutational analysis pipeline that uses standardized sequence-based inputs along with multiple types of clinical data to establish correlations among mutation sites, affected genes and pathways, and to ultimately separate the commonly abundant passenger mutations from the truly significant events. In other words, we aim to determine the Mutational Significance in Cancer (MuSiC) for these large data sets. The integration of analytical operations in the MuSiC framework is widely applicable to a broad set of tumor types and offers the benefits of automation as well as standardization. Herein, we describe the computational structure and statistical underpinnings of the MuSiC pipeline and demonstrate its performance using 316 ovarian cancer samples from the TCGA ovarian cancer project. MuSiC correctly confirms many expected results, and identifies several potentially novel avenues for discovery.
Subject(s)
DNA Mutational Analysis/methods , Molecular Sequence Annotation/methods , Mutation , Ovarian Neoplasms/genetics , Software , Algorithms , BRCA1 Protein/genetics , Computational Biology/methods , DNA Mutational Analysis/standards , Female , Genes, Neoplasm , Humans , Reproducibility of ResultsABSTRACT
The sensitivity of massively-parallel sequencing has confirmed that most cancers are oligoclonal, with subpopulations of neoplastic cells harboring distinct mutations. A fine resolution view of this clonal architecture provides insight into tumor heterogeneity, evolution, and treatment response, all of which may have clinical implications. Single tumor analysis already contributes to understanding these phenomena. However, cryptic subclones are frequently revealed by additional patient samples (e.g., collected at relapse or following treatment), indicating that accurately characterizing a tumor requires analyzing multiple samples from the same patient. To address this need, we present SciClone, a computational method that identifies the number and genetic composition of subclones by analyzing the variant allele frequencies of somatic mutations. We use it to detect subclones in acute myeloid leukemia and breast cancer samples that, though present at disease onset, are not evident from a single primary tumor sample. By doing so, we can track tumor evolution and identify the spatial origins of cells resisting therapy.
Subject(s)
Clonal Evolution/genetics , Computational Biology/methods , Mutation/genetics , Neoplasms/classification , Neoplasms/genetics , Breast Neoplasms/genetics , Female , Gene Frequency/genetics , Humans , Leukemia, Myeloid, Acute/genetics , Models, Statistical , Neoplastic ProcessesABSTRACT
Search strategies are currently of great interest, with reports on foraging ranging from albatrosses and spider monkeys to microzooplankton. Here, we investigate the role of noise in optimizing search strategies. We focus on the zooplankton Daphnia, which move in successive sequences consisting of a hop, a pause and a turn through an angle. Recent experiments have shown that their turning angle distributions (TADs) and underlying noise intensities are similar across species and age groups, suggesting an evolutionary origin of this internal noise. We explore this hypothesis further with a digital simulation (EVO) based solely on the three central Darwinian themes: inheritability, variability and survivability. Separate simulations utilizing stochastic resonance (SR) indicate that foraging success, and hence fitness, is maximized at an optimum TAD noise intensity, which is represented by the distribution's characteristic width, sigma. In both the EVO and SR simulations, foraging success is the criterion, and the results are the predicted characteristic widths of the TADs that maximize success. Our results are twofold: (1) the evolving characteristic widths achieve stasis after many generations; (2) as a hop length parameter is changed, variations in the evolved widths generated by EVO parallel those predicted by SR. These findings provide support for the hypotheses that (1) sigma is an evolved quantity and that (2) SR plays a role in evolution.
Subject(s)
Biological Evolution , Daphnia/physiology , Ecosystem , Feeding Behavior/physiology , Animals , Computer Simulation , Genetic Variation , Longevity , Models, Biological , Species Specificity , Stochastic Processes , Survival Analysis , Zooplankton/physiologyABSTRACT
We explore the variability that animals display in their movement choices as they forage in a finite-sized food patch with a uniform food distribution, and present a framework for how these choices may be adjusted to optimize foraging efficiency. Inspired by experimental studies of the zooplankton Daphnia, we model foraging animals as "agents" moving in two dimensions in repeated and successive sequences of hops, pauses, and turns. For Daphnia and other species, critical movement parameters such as hop lengths, pause times, and turning angles are typically reported as probability density functions. Similarly, the agents in our simulations choose their movement parameters at random from such distributions. Each distribution is defined by a characteristic width, which we interpret as a "noise width," available to be tuned for increased foraging efficiency. We investigate the sensitivity of the system by measuring the food gathered by the agents as the turning angle and hop length noise widths are varied. In all cases, we find a maximum in food gathered at some particular value of the noise width in question, suggesting that these results can be considered robust examples of natural stochastic resonance.
Subject(s)
Appetitive Behavior/physiology , Daphnia/physiology , Models, Biological , Animals , Ecosystem , Feeding Behavior/physiology , Motor Activity/physiology , Stochastic ProcessesABSTRACT
Inactivation of Ras GTPase activating proteins (RasGAPs) can activate Ras, increasing the risk for tumor development. Utilizing a melanoma whole genome sequencing (WGS) data from 13 patients, we identified two novel, clustered somatic missense mutations (Y472H and L481F) in RASA1 (RAS p21 protein activator 1, also called p120RasGAP). We have shown that wild type RASA1, but not identified mutants, suppresses soft agar colony formation and tumor growth of BRAF mutated melanoma cell lines via its RasGAP activity toward R-Ras (related RAS viral (r-ras) oncogene homolog) isoform. Moreover, R-Ras increased and RASA1 suppressed Ral-A activation among Ras downstream effectors. In addition to mutations, loss of RASA1 expression was frequently observed in metastatic melanoma samples on melanoma tissue microarray (TMA) and a low level of RASA1 mRNA expression was associated with decreased overall survival in melanoma patients with BRAF mutations. Thus, these data support that RASA1 is inactivated by mutation or by suppressed expression in melanoma and that RASA1 plays a tumor suppressive role by inhibiting R-Ras, a previously less appreciated member of the Ras small GTPases.
Subject(s)
Biomarkers, Tumor/metabolism , Cell Transformation, Neoplastic/pathology , Melanoma/pathology , Mutation , p120 GTPase Activating Protein/metabolism , ras Proteins/metabolism , Amino Acid Sequence , Animals , Apoptosis , Biomarkers, Tumor/genetics , Cell Proliferation , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Follow-Up Studies , Humans , Melanoma/genetics , Melanoma/metabolism , Mice , Mice, Nude , Prognosis , Retrospective Studies , Signal Transduction , Survival Rate , Tumor Cells, Cultured , Xenograft Model Antitumor Assays , p120 GTPase Activating Protein/antagonists & inhibitors , p120 GTPase Activating Protein/genetics , ras Proteins/geneticsABSTRACT
To reveal the clonal architecture of melanoma and associated driver mutations, whole genome sequencing (WGS) and targeted extension sequencing were used to characterize 124 melanoma cases. Significantly mutated gene analysis using 13 WGS cases and 15 additional paired extension cases identified known melanoma genes such as BRAF, NRAS, and CDKN2A, as well as a novel gene EPHA3, previously implicated in other cancer types. Extension studies using tumors from another 96 patients discovered a large number of truncation mutations in tumor suppressors (TP53 and RB1), protein phosphatases (e.g., PTEN, PTPRB, PTPRD, and PTPRT), as well as chromatin remodeling genes (e.g., ASXL3, MLL2, and ARID2). Deep sequencing of mutations revealed subclones in the majority of metastatic tumors from 13 WGS cases. Validated mutations from 12 out of 13 WGS patients exhibited a predominant UV signature characterized by a high frequency of C->T transitions occurring at the 3' base of dipyrimidine sequences while one patient (MEL9) with a hypermutator phenotype lacked this signature. Strikingly, a subclonal mutation signature analysis revealed that the founding clone in MEL9 exhibited UV signature but the secondary clone did not, suggesting different mutational mechanisms for two clonal populations from the same tumor. Further analysis of four metastases from different geographic locations in 2 melanoma cases revealed phylogenetic relationships and highlighted the genetic alterations responsible for differential drug resistance among metastatic tumors. Our study suggests that clonal evaluation is crucial for understanding tumor etiology and drug resistance in melanoma.
Subject(s)
GTP Phosphohydrolases/genetics , Genome, Human/genetics , Melanoma/genetics , Membrane Proteins/genetics , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/genetics , Base Sequence , DNA Mutational Analysis , Genes, p16 , Humans , Phosphoprotein Phosphatases/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptor, EphA3 , Sequence Analysis, DNA , Tumor Suppressor Proteins/geneticsABSTRACT
The role of mutation rate in optimizing key features of evolutionary dynamics has recently been investigated in various computational models. Here, we address the related question of how maximum mutation size affects the formation of species in a simple computational evolutionary model. We find that the number of species is maximized for intermediate values of a mutation size parameter mu; the result is observed for evolving organisms on a randomly changing landscape as well as in a version of the model where negative feedback exists between the local population size and the fitness provided by the landscape. The same result is observed for various distributions of mutation values within the limits set by mu. When organisms with various values of mu compete against each other, those with intermediate mu values are found to survive. The surviving values of mu from these competition simulations, however, do not necessarily coincide with the values that maximize the number of species. These results suggest that various complex factors are involved in determining optimal mutation parameters for any population, and may also suggest approaches for building a computational bridge between the (micro) dynamics of mutations at the level of individual organisms and (macro) evolutionary dynamics at the species level.